Financial Data and Key Metrics Changes - The company ended 2024 with $75.1 million in cash, restricted cash, cash equivalents, and investments [42] - Collaboration and license revenue related to the Kyorin agreement was $0.2 million for the year ended 2024 [43] - Research and development expenses were $54.4 million for the year ended 2024, primarily for clinical trial costs [43] - General and administrative expenses were $13.8 million for the year ended 2024 [43] - The company raised approximately $18.8 million in gross proceeds from its at-the-market offering program after the end of Q4 2024 [42] Business Line Data and Key Metrics Changes - The company completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, the largest interventional study ever conducted in this area [10][11] - The EFZO-FIT study enrolled 268 patients at 85 centers in 9 countries [12] - The company is also conducting the EFZO-CONNECT study for ILD-related systemic sclerosis, which is currently enrolling patients [28] Market Data and Key Metrics Changes - The company estimates a total global market opportunity for efzofitimod in ILD at $2 billion to $5 billion, with sarcoidosis representing a significant portion of that range [25] - A third-party claims analysis confirmed that the number of patients diagnosed with lung involvement is 30% higher than previously estimated, indicating a larger market opportunity [22] Company Strategy and Development Direction - The company aims to position efzofitimod as a potential frontline steroid-reducing agent in patients with moderate to severe sarcoidosis, addressing 50% to 75% of all sarcoidosis patients [24] - The company is preparing for commercial readiness and has appointed Eric Benevich to its Board of Directors to assist in this effort [26] - The company is exploring additional therapeutic areas for efzofitimod, including scleroderma and other fibrotic diseases, based on its unique mechanisms of action [39][106] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the favorable safety profile of efzofitimod and the potential for a significant market opportunity with little competition [47] - The company is optimistic about the upcoming Phase 3 EFZO-FIT readout and potential filing of a Biologics License Application for efzofitimod [44] - Management highlighted the importance of the recent publication in Science Translational Medicine, which validates the drug's mechanism of action [47] Other Important Information - The company has conducted four positive data and safety monitoring board reviews for the EFZO-FIT study, all of which have identified no safety concerns [14] - The company plans to present findings related to baseline demographics and disease characteristics at the upcoming American Thoracic Society Conference [15] Q&A Session Summary Question: Can you shed some light on how measuring the absolute change in steroid reduction impacts the trial? - Management explained that the new approach simplifies data analysis and maintains over 90% powering for the trial [54] Question: What is the percent of patients in the trial rolling over into the expanded access program? - Management noted that interest in the EAP is robust, but specific numbers are difficult to provide due to varying regulatory requirements across countries [56] Question: Was the market research around managing patients with steroid reduction related to the change in the statistical analysis plan? - Management clarified that the change was based on discussions with the FDA and aimed at simplifying the analysis [70] Question: What are the expected results from the interim analysis for the scleroderma program? - Management indicated that the focus will be on skin assessments, which are critical for understanding the drug's impact on quality of life [104] Question: How should we think about the durability of the drug impact with the new analysis approach? - Management emphasized that durability is important and will be assessed through various endpoints, including time to relapse [87]